Further Data Support Safety, Efficacy of Takeda’s Entyvio for UC, Crohn’s

Further Data Support Safety, Efficacy of Takeda’s Entyvio for UC, Crohn’s
Takeda Pharmaceuticals, which is on the forefront of treating ulcerative colitis and Crohn's disease with the newly launched Entyvio (vedolizumab), will present data concerning the open-label extension phase 3 study of patients receiving Entyvio for a total of two years. The study, GEMINI LTS (Long-Term Safety), will be discussed in three presentations at the 21st United European Gastroenterology Week (UEGW) in Vienna, Austria, and related data will be presented in another abstract. "Ulcerative colitis and Crohn's disease are chronic diseases that can have a serious impact on patients. As physicians, our aim is to help patients achieve and maintain disease remission," said Dr. Severine Vermeire,  of the University Hospitals Leuven in Belgium, in a news article from Drug Discovery & Development Magazine. "Current findings from the long-term extension study add to the evidence bank of vedolizumab as a long-term treatment option for people with ulcerative colitis and Crohn's disease." A preview of findings has already been discussed. The majority of Crohn's disease patients who enrolled in GEMINI LTS (after completing or withdrawing from GEMINI 2) saw a benefit from continuing treatment. Clinical remission was achieved by 61% and 74% of patients at weeks 52 and 104, respectively, and a clinical response was seen in 81% and 74% of patients, respectively. The same was true for ulcerative colitis patients, who enrolled in  GEMINI LTS following GEMINI 1. Clinical remission was achieved by 66% and 73% of patients at 52 and 104 weeks, respectively, and 79% and 80% of patients saw a clinical response, respectively. During GEMINI LTS, vedolizumab was administered intravenously every four weeks in doses of 300 mg each. As a gut-selective humanized monoclonal antib
Subscribe or to access all post and page content.